Summit Therapeutics Inc. - 8-K Filing
FDA issues Complete Response Letter for ivonescimab BLA in NSCLC due to lack of statistically significant overall survival improvement.
Tickers: $SMMT
Read the full article at SEC EDGAR
Part of the story Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab Combination Therapy (4 articles)